Clinical Trial

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2017-08-16; most recent amendment 2024-12-04.
Status change: Recruiting → Active, Not Recruiting 2019-05-22
Status change: Not Yet Recruiting → Recruiting 2017-09-29
Trial Details
NCT Number NCT03252808
Lead Sponsor Takara Bio Inc.
Conditions Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Enrollment 36 participants
Start Date 2017-09-25
Primary Completion 2020-02-19 (estimated)
Study Completion 2035-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-09